What’s new this week in Indian MedTech
8 to 15 November 2026
A week when policy and plain economics did most of the talking in Indian MedTech. The government extended the medical devices PLI scheme to 2035-36 with about Rs 2,700 crore still available, trade investigators recommended a five-year anti-dumping duty on examination gloves from Thailand and Malaysia, and Poly Medicure and Shalby told investors how they plan to grow and cut costs. On the startup side, Rymo Technologies brought in 1Crowd for affordable robotic rehabilitation and Froncort.AI won USD 2.3 million from Google.org, while cardiologists in Kerala asked for a review of the curbs on reprocessing single-use devices and doctors questioned the health claims of Deepinder Goyal’s Temple wearable.
1. Government extends the medical devices PLI scheme to 2035-36, with about Rs 2,700 crore available
On 10 November the Department of Pharmaceuticals invited fresh applications under the Production Linked Incentive Scheme for Promoting Domestic Manufacturing of Medical Devices (PLI-MD), now extended to 2035-36, with approximately Rs 2,700 crore of outlay to be used. Applicants get three years to set up facilities in four target segments: consumables, disposables and implants; critical components; high-end devices at a nascent stage of local manufacturing; and high-end devices that are only assembled in India today. Average tapering incentives are about 5%, 9%, 9% and 6% respectively. The minimum sales threshold to claim incentives has been dropped, the minimum investment requirement has been trimmed, and the application window will stay open for a long period. The government says the first phase led to domestic manufacturing of more than 60 high-end devices and components, including 1.5T MRI, CT scanners, LINAC and cath labs, with production worth over Rs 16,000 crore. The Indian Express noted that almost 80% of the original Rs 3,420 crore outlay had gone unused. It matters because the new rules openly target components and high-end equipment such as 3T MRI, PET-CT and ultrasound probes, which is exactly where India still imports most of what it uses.
Source: Press Information Bureau and The Indian Express
2. DGTR recommends a five-year anti-dumping duty on medical examination gloves from Thailand and Malaysia
Medical Buyer reported on 10 November that the Directorate General of Trade Remedies, the investigation arm of the commerce ministry, has recommended a definitive anti-dumping duty on medical examination rubber gloves originating in or exported from Thailand and Malaysia. The proposed duty ranges from USD 442 to USD 565 per one lakh pieces, about Rs 42,650 to Rs 54,520, and would apply for five years. The recommendation is not automatically binding and now goes to the Ministry of Finance for a final decision. It matters because gloves are one of the highest volume consumables any hospital buys, so a notified duty would protect Indian makers but could raise landed costs for importers, distributors and hospital procurement teams.
Source: Medical Buyer
3. Rymo Technologies brings in 1Crowd to make robotic rehabilitation more affordable
On 12 November early-stage fund 1Crowd said it has invested in Rymo Technologies, a Navi Mumbai company founded in 2020 by Chirag Shah, its CEO, and Abhishek Rai, which builds robotic and AI-assisted rehabilitation systems for patients recovering from neurological and orthopaedic conditions. The amount was not disclosed. Rymo’s portfolio spans robotic rehabilitation systems such as the flagship Mobi-L, balance trainers, XR and VR based therapy, and upcoming functional electrical stimulation devices. 1Crowd noted that imported robotic rehabilitation systems can cost Rs 1 to 1.5 crore and said Rymo’s solutions are about ten times more affordable. Co-Founder and Partner Natasha Kothari said healthcare and medtech make up about 20% of the 1Crowd portfolio. Rymo raised a seed round of about Rs 10 crore led by IAN Group in March 2026. It matters because rehabilitation is a huge, underserved need in India, and a device priced for smaller physiotherapy centres and mid-sized hospitals can reach patients that imported machines never will.
Source: The Hindu BusinessLine and Inc Business
4. Froncort.AI wins USD 2.3 million from Google.org for AI-based disease surveillance
On 10 November Inc42 reported that Froncort.AI, founded in 2024 by physician-scientist Dr Ujjwal Rao, has secured USD 2.3 million (about Rs 21.5 crore) from Google.org, plus USD 200,000 in Google Cloud credits and pro bono support from Google’s AI specialists. It is one of 15 organisations selected globally for Google.org’s Impact Challenge: AI for Government Innovation. The money will build mAI-NETRA, a mobile version of its AI-NETRA platform, which combines government health data, satellite imagery and Google’s Earth AI models to point frontline workers to high-risk clusters. In a validation study with Maharashtra’s state TB programme, the company says teams found a similar number of confirmed pulmonary TB cases while screening two-thirds fewer people, and cost per confirmed case fell from about USD 29,000 to USD 10,000. The platform will extend to TB, leprosy, malaria, dengue, cholera and leptospirosis, and will be released as an open-source blueprint for governments. Froncort.AI also runs RegDoc, a regulatory submissions platform used by device makers and pharma companies. It matters because it shows how Indian AI teams are finding non-dilutive global money by solving public health problems at state scale.
Source: Inc42
5. Poly Medicure targets doubling revenue by FY30 and welcomes PLI 2.0
On 14 November Medical Buyer, citing CNBC-TV18, reported that Poly Medicure Managing Director Himanshu Baid expects the company to double revenue by FY30, with 80% to 90% of growth from existing businesses and 10% to 15% from acquisitions, though no new acquisition is in the pipeline. Priorities are widening orthopaedics across trauma, joints and implants, and moving in cardiology towards interventional and eventually structural heart products. Baid said the extended PLI scheme covers most of what Poly Medicure makes and plans to launch in the next one to two years, and called component manufacturing one of its biggest opportunities. He also said Chinese renal products are being routed through FTA partner countries such as Malaysia at zero customs duty, and that an anti-dumping investigation has been initiated. In its Q2 FY27 call transcript filed on 11 November, the company reported consolidated H1 FY27 revenue of Rs 1,106 crore, up 31%. It matters because one of India’s largest device exporters is publicly tying its growth plan to PLI 2.0 and to trade remedies, which tells you where the industry’s lobbying energy is going.
Source: Medical Buyer and Kalkine
6. Shalby expects its new supply chain to cut implant manufacturing costs by a further 30% to 40%
Medical Buyer reported on 13 November that Shalby Limited told investors in its Q2 FY27 call that a new MedTech supply chain should cut current implant manufacturing cost by a further 30% to 40%, after costs had already fallen by more than half since it acquired its US implant facility in 2021. Management expects the savings to start reaching the profit and loss account in Q4 FY27, with a full-quarter effect in Q1 FY28. MedTech EBITDA was Rs 36 lakh in Q2 FY27, up from Rs 16 lakh the quarter before, its fifth consecutive EBITDA-positive quarter, and MedTech inventory days fell to 784 from about 1,200 a year earlier. Shalby also cited approvals in Malaysia, Argentina and Nepal and said it expects an NPPA implant price revision around mid-November, which was management’s expectation rather than a confirmed decision. It matters because a hospital group that owns a US FDA implant line is trying to make the economics work by moving manufacturing cost, the same question every Indian orthopaedic maker faces against imported brands.
Source: Medical Buyer
7. Kerala cardiologists ask DGHS to review curbs on reprocessing single-use devices
On 10 November Medical Buyer carried a PTI report that the Cardiological Society of India’s Kerala Chapter, at its annual conference, sought a review of DGHS restrictions on reprocessing medical devices labelled for single use. Chapter president Dr Asokan P K and organising chairman Dr Prathap Kumar N said the cost of complex angioplasty, especially procedures needing several specialised devices, often exceeds government insurance packages, and asked whether select catheters, guidewires and other equipment could be safely reprocessed under scientifically validated protocols. Dr Prathap Kumar stressed that patient safety must remain paramount, with validated sterilisation, functional testing and strict regulatory oversight. Medical Buyer followed up on 13 November with concerns over the impact of the ban on dialysis and cardiac care costs in Kerala. It matters because device makers, hospitals and regulators are now in an open debate about safety versus affordability, and the outcome will shape demand for disposables across India.
Source: Medical Buyer (PTI) and Medical Buyer
8. Doctors question claims of Deepinder Goyal’s Temple wearable and call for regulator review
On 12 November Reuters, carried by The Hindu, reported that Temple, a head-worn wearable developed by Deepinder Goyal, co-founder of Eternal, the parent of Zomato, has drawn criticism from doctors over claims that its BrainFlow feature tracks blood flow to the brain in real time. The device weighs under 2 grams, sticks to the temple and costs Rs 85,000 (about USD 907). Hepatologist Dr Cyriac Philips, known as “TheLiverDoc”, called it “the biggest health scam”, and paediatrician and nephrologist Dr Sanjeev Bagai said it had “no formal approval or clearance”. Goyal says Temple is a fitness tracker and wellness device, not a medical one, while the company said some metrics would eventually need regulatory approval. Temple raised USD 54 million in February at a valuation of about USD 190 million, and Goyal said it has received orders from more than 62 countries since 1 November. It matters because the line between wellness gadget and medical device is now a public question in India, and CDSCO’s answer will matter to every wearable startup.
Source: The Hindu (Reuters) and Medical Buyer
Gary’s take
I lived in India and have worked with Indian teams for many years, and this week felt very familiar to me. The headlines were about policy and money, but the real story is cost. PLI 2.0 finally gives makers three years to build and stops punishing them with sales thresholds, which is what the industry asked for, and Poly Medicure said so plainly. The glove duty, the Chinese renal products coming in through Malaysia and Shalby’s push to take 30% to 40% out of implant costs are all the same conversation: can India make good devices at a price Indian hospitals and patients can afford? Rymo’s rehabilitation robots at a tenth of the imported price are a lovely answer to that question. The Kerala cardiologists and the Temple debate remind me of the other half, which is trust. Affordability without safety, or bold claims without evidence, will not last. If you are building or selling in India, plan for both from day one.
Which of these Indian stories matters most for your company, and is there a state, therapy area or company type you would like me to cover in more depth next week? You are always welcome to write to me directly, and you can find more of my articles, and book a short introductory call, at synergenmedtech.com.
Sources note: all items were found through a public web scan of the week and each was checked against the linked original source. Poly Medicure’s half-year figures come from its Q2 FY27 earnings call held on 5 November, with the transcript filed on 11 November. The Shalby call date was not stated in the source.
If you’d like to follow along, you can find us here:
Website: synergenmedtech.com
LinkedIn: linkedin.com/company/100981535
YouTube: youtube.com/@synergenmedtech


Leave a Reply